AG真人官方

UBS AG London Branch is offering Contingent Income Auto-Callable Securities linked to the common stock of Spotify Technology S.A. (SPOT).

• Tenor: Approximately 24 months (expected maturity 15 Jul 2027).
• Coupon: $30.75 per $1,000 note (12.30% p.a.) payable on each quarterly determination date only if SPOT closes 鈮� 50% of the initial price (the 鈥渄ownside threshold鈥�). Missed coupons may be recovered later via the 鈥渕emory鈥� feature.
• Early Call: If SPOT closes 鈮� 100% of the initial price on any determination date (other than final), the note is automatically redeemed for par plus the applicable coupon(s).
• Principal Repayment: 鈥� If not called and SPOT final price 鈮� 50% of initial, investor receives par plus final (and any unpaid) coupons. 鈥� If SPOT final price < 50% of initial, investor receives physical settlement of SPOT shares equal to the exchange ratio (par 梅 initial price), worth substantially less than par and potentially zero.
• Issue price: $1,000; estimated initial value $935.50鈥�$965.50 (reflects fees and hedging costs).
• Fees: 2.00% total (1.50% sales commission, 0.50% structuring fee). Proceeds to issuer 98% of par.
• Secondary market: Not exchange-listed; UBS Securities LLC may provide limited liquidity but is not obligated to do so.
• Credit risk: Unsecured, unsubordinated obligations of UBS AG; all payments subject to UBS creditworthiness.

Investor profile: Suitable only for investors who can tolerate equity-like downside, limited upside, issuer credit risk and potential illiquidity, and who seek high contingent income with possible early redemption.

On July 8, 2025, Longeveron Inc. (Nasdaq: LGVN) filed a Form 8-K announcing a U.S. FDA clearance of its Investigational New Drug (IND) application for laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young, healthy donor bone marrow. The clearance authorizes the Company to initiate a Phase 2 clinical trial in pediatric dilated cardiomyopathy (DCM), a life-threatening heart condition with limited treatment options. No start-date, enrollment targets, or financial terms were included in the filing. The event represents a key regulatory milestone that advances Longeveron鈥檚 lead asset into mid-stage development and broadens its clinical program into the pediatric arena. Aside from the attached press release (Exhibit 99.1), the 8-K contains no additional financial statements, earnings data, or transactional disclosures.

On July 8, 2025, Longeveron Inc. (Nasdaq: LGVN) filed a Form 8-K announcing a U.S. FDA clearance of its Investigational New Drug (IND) application for laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young, healthy donor bone marrow. The clearance authorizes the Company to initiate a Phase 2 clinical trial in pediatric dilated cardiomyopathy (DCM), a life-threatening heart condition with limited treatment options. No start-date, enrollment targets, or financial terms were included in the filing. The event represents a key regulatory milestone that advances Longeveron鈥檚 lead asset into mid-stage development and broadens its clinical program into the pediatric arena. Aside from the attached press release (Exhibit 99.1), the 8-K contains no additional financial statements, earnings data, or transactional disclosures.

Marsh & McLennan Companies, Inc. (MMC) has filed a Form 8-K dated July 9, 2025 announcing that the Board has appointed Bruce Broussard, 63, as an independent director effective immediately. He will also join the Board鈥檚 Audit Committee after the directors determined that he meets all applicable independence and financial-literacy requirements. As a non-management director, Mr. Broussard will receive the standard compensation package previously disclosed for independent directors (see Exhibit 10.1 to MMC鈥檚 Q2-2024 Form 10-Q). A press release detailing the appointment is furnished as Exhibit 99.1 and incorporated by reference. No other material changes, financial results, or transactions are reported in this filing.

Marsh & McLennan Companies, Inc. (MMC) has filed a Form 8-K dated July 9, 2025 announcing that the Board has appointed Bruce Broussard, 63, as an independent director effective immediately. He will also join the Board鈥檚 Audit Committee after the directors determined that he meets all applicable independence and financial-literacy requirements. As a non-management director, Mr. Broussard will receive the standard compensation package previously disclosed for independent directors (see Exhibit 10.1 to MMC鈥檚 Q2-2024 Form 10-Q). A press release detailing the appointment is furnished as Exhibit 99.1 and incorporated by reference. No other material changes, financial results, or transactions are reported in this filing.

Armada Hoffler Properties, Inc. (NYSE: AHH) filed an 8-K announcing an upcoming change of external auditors. On 18 June 2025 the Board鈥檚 Audit Committee approved the dismissal of Ernst & Young LLP (EY) and the engagement of KPMG LLP as the company鈥檚 independent registered public accounting firm beginning with the audit of fiscal year ending 31 Dec 2026. The switch will become effective immediately after the company files its Form 10-K for FY 2025.

EY will continue to audit FY 2025 and remains in place until the effective date. EY鈥檚 reports for FY 2023 and FY 2024 were unqualified and contained no adverse opinions, disclaimers, or modifications related to uncertainty, scope or principles. Management disclosed no disagreements or 鈥渞eportable events鈥� with EY during the past two fiscal years or the subsequent interim period.

The company has requested EY to provide the SEC with a concurrence letter (filed as Exhibit 16.1 dated 24 June 2025). Management also stated that it did not consult KPMG on any matters described in Item 304(a)(2) of Regulation S-K prior to the appointment. An amended 8-K will be filed later to provide the precise dates of EY鈥檚 termination and KPMG鈥檚 engagement.

Because the change follows clean audit opinions and no noted disputes, the filing appears procedural rather than indicative of accounting issues. Investors should nonetheless monitor forthcoming disclosures to ensure a seamless transition and continued reporting quality.

Form 4 鈥� Armada Hoffler Properties, Inc. (AHH)

Director George F. Allen reported the grant of 7,938 unvested Time-Based LTIP Units in the company鈥檚 operating partnership on 18-Jun-2025. The units carry no purchase price, convert into common units once vested, and may be exchanged for cash or one AHH common share two years after the grant date, subject to the partnership agreement.

Post-grant holdings stand at 17,564 Time-Based LTIP Units, 29,676 common shares and 2,000 Series A 6.75 % preferred shares, all held directly. No open-market purchases or sales of common stock were disclosed; the filing reflects routine director equity compensation.

The size of the award is modest relative to AHH鈥檚 outstanding equity and is unlikely to have a material dilutive effect. Nevertheless, the grant incrementally aligns the director鈥檚 interests with long-term shareholder value as the units vest at the 2026 Annual Meeting of Stockholders.